Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a biotechnology company that is paving the way for innovation in mental health treatment. With a strong focus on developing drugs with novel mechanisms of action for high unmet need psychiatric disorders, the company's flagship product, COMP360, has shown great promise in treating treatment-resistant depression and PTSD. The company's strong financial position, with cash runway into 2028, and a low-risk regulatory path, sets it up for a successful launch and growth potential.

Bears say

Compass Pathways is heavily reliant on the success of its proprietary synthetic psilocybin formulation, COMP360, and the positive results from its late-stage clinical trials for the treatment of mental health conditions. However, the company's management has been criticized for their framing of outcomes and the lack of meaningful support during therapy sessions, raising doubts about the effectiveness of their treatment. With a limited product portfolio and high stakes on clinical trials, any setbacks or negative outcomes could significantly impact the company's long-term success and profitability.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.